The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

September 27, 2022 • By Michael Putman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June 2017, when the core leadership team formed by the ACR first met in person. The ACR also convened expert and voting panels. Together, the core team and the two panels determined the project’s scope. Members of the literature review team assembled evidence using the most recent nomenclature system for vasculitis, the 2012 Chapel Hill Consensus Conference nomenclature.1 A panel of patients contributed as well. In this series, we discuss the updated recommendations with authors who contributed to each guideline. Read previous installments in this series.

You Might Also Like
  • Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis
  • New Insights into the Management of Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Explore This Issue
October 2022

We continue our series with Mehrdad Maz, MD, an author of the ACR/VF guideline for GCA. Dr. Maz is a professor of medicine, director of the rheumatology fellowship training program, and chief of the Division of Allergy, Clinical Immunology, and Rheumatology at the University of Kansas Medical Center, Kansas City, Kans.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

From the guideline—Recommendation: For patients with suspected GCA, we conditionally recommend temporal artery biopsy over temporal artery ultrasound for establishing a diagnosis of GCA.

Q: I believe some practical considerations led to a conditional recommendation for temporal biopsy over ultrasound. Why did the panel end up on that side of the debate?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Maz: The short answer is that this recommendation is not intended to discourage the use of ultrasound in the evaluation of patients with suspected GCA.2 Also, the objective of this guideline was to provide evidence-based recommendations and expert guidance in the U.S. Out of 22 recommendations for GCA, only one was a strong recommendation. The remainder were conditional, including the one to consider temporal artery biopsy over the use of ultrasound of the temporal artery for diagnosis of GCA.

It’s important to explain what we mean by a conditional vs. strong recommendation because it pertains to your question.

Strong recommendations are typically supported by moderate- or high-quality evidence, such as what you see in randomized controlled trials. A strong recommendation is one that would apply to all, or almost all, patients, and so only a small proportion of clinicians and patients would not want to follow the recommendation.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

A conditional recommendation is supported by lower quality evidence. A conditional recommendation would apply to most patients, but the alternative is a reasonable consideration. As we go through these discussions, let’s keep these definitions in mind.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Guidelines, Vasculitis Tagged With: GCA, giant cell arteritis (GCA), guideline, VasculitisIssue: October 2022

You Might Also Like:
  • Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis
  • New Insights into the Management of Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)